Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis


Haematologica 2020 [Epub ahead of print]

Citation: Sheila Bohler, Sehar Afreen, Juncal Fernandez-Orth, Eva-Maria Demmerath, Christian Molnar, Ying Wu, Julia Miriam Weiss, Venugopal Rao Mittapalli, Lukas Konstantinidis, Hagen Schmal, Mirjam Kunze, and Miriam Erlacher. Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis.
Haematologica. 2020; 105:xxx

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis

Sheila Bohler 1,2, Sehar Afreen1, Juncal Fernandez-Orth1, Eva-Maria Demmerath1, Christian Molnar1,2,3, Ying Wu1,2, Julia Miriam Weiss1, Venugopal Rao Mittapalli1, Lukas Konstantinidis4, Hagen Schmal4, Mirjam Kunze5, Miriam Erlacher1,6

Affiliations
1. Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Germany.
2. Faculty of Biology, University of Freiburg, Germany.
3. Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Germany
4. Department of Orthopedics and Trauma Surgery, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
5. Department of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Germany
6. German Cancer Consortium (DKTK), Freiburg, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.

* Corresponding author

Running title: MCL1 in human hematopoiesis

*Address of correspondence:
Miriam Erlacher, MD PhD
Department of Pediatrics and Adolescent Medicine
Division of Pediatric Hematology and Oncology
University Medical Center Freiburg
Mathildenhöhe 1
Freiburg 79106, Germany.
Acknowledgements

We thank the members of the DFG-FOR2036 consortium for insightful discussions, Nora Kaltenbach and Caroline Ambs for excellent technical assistance, the animal care-takers of the Center for Experimental Models and Transgenic Services (CEMT) for animal care and the Lighthouse Fluorescence Technologies Core Facility, Freiburg for cell sorting and maintenance of flow cytometers. We are grateful to Heike Pahl for providing us lentiviral constructs and Albert Gründer for support during initial cloning. This work was supported by grants of the German Academic Exchange Service (DAAD) (funding program 57048249 to SA) and the German Research Foundation (DFG-FOR2036, ER599/3-1 and ER599/3-2 to ME). The authors declare no conflict of interest.

Author contribution

SB, SA, JFO, EMD, CM, YW, JMW and VRM designed and performed experiments; SB, SA, JFO, EMD, YW and ME analyzed and interpreted data; SB, SA and ME wrote the manuscript; LK, HS and MK provided human samples. The authors declare no conflict of interest.

Abstract

BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already FDA-approved, BCL-XL and MCL-1 inhibitors are currently in early clinical trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic system, we used RNAi and the small molecule inhibitor S63845 on cord blood-derived CD34+ cells. Both approaches resulted in almost complete depletion of human hematopoietic stem and progenitor cells. As a consequence,
maturation into the different hematopoietic lineages was severely restricted and CD34+ cells expressing MCL-1 shRNA showed a very limited engraftment potential upon xenotransplantation. In contrast, mature blood cells survived normally in the absence of MCL-1. Combined inhibition of MCL-1 and BCL-XL resulted in synergistic effects with relevant loss of colony-forming HSPCs already at inhibitor concentrations of 0.1 µM each, indicating “synthetic lethality” of the two BH3-mimetics in the hematopoietic system.

Introduction

BH3-mimetics represent a novel and very promising group of anticancer drugs, with venetoclax being the first compound approved by the FDA. They act by directly inhibiting anti-apoptotic BCL-2 proteins that prevent the intrinsic apoptosis pathway and thereby ensure survival of every human cell. BCL-2 and its homologues BCL-XL, MCL-1, BFL1/A1 and BCL-W bind to and inhibit BAX and BAK, two downstream pro-apoptotic effector BCL-2 proteins which upon activation lead to permeabilization of the outer mitochondrial membrane. As a consequence, cytochrome c is released into the cytosol, a process regarded as “point of no return” for apoptosis initiation. In the cytosol, cytochrome c together with APAF1 and procaspase 9 molecules form a large complex termed apoptosome, in which caspase 9 is activated. Caspase 9 then activates the effector caspases 3, 6 and 7 which eventually degrade vital cellular structures and execute cell death. This whole process is regulated by upstream pro-apoptotic proteins that also belong to the large BCL-2 family but share only the BH3 (BCL2 homology 3) domain with the other members of the anti-apoptotic BCL-2 family. BH3-only proteins are upregulated or activated upon given stress signals and then bind and inhibit the anti-apoptotic BCL-2 proteins. As a consequence, BAX and BAK are released leading to apoptosis. As their name says, BH3-mimetics imitate mode of action of the BH3-only proteins. While BH3-only proteins are tightly regulated and only activated upon lethal stress signals, BH3-mimetics are able to bypass this mode of activation. Similar to BH3-only proteins, every BH3-mimetic available so far has specific binding affinities to one or more anti-apoptotic BCL-2 proteins (Suppl. Figure 1A). Navitoclax (ABT-
and its intravenously used precursor drug, ABT-737 bind to BCL-2, BCL-XL and BCL-W. The drug showed good efficacies against non-small lung carcinoma and hematological malignancies. However, its side effects on the hematopoietic system precluded its full clinical exploration and FDA approval. This indicated that a combined inhibition of more than one pro-survival BCL-2 protein might impede survival of healthy body cells. Later, a BCL-2 specific inhibitor called venetoclax (ABT-199) found its way into clinical trials. Thanks to the much less severe side effects, it was FDA-approved in 2016 as a second-line treatment of chronic lymphocytic leukemia (CLL) with 17p deletion, and in 2019 for the treatment of all adult CLL and small lymphocytic lymphoma patients. For AML, venetoclax was FDA-approved only in combination with hypomethylating agents.

Unfortunately like other cytotoxic drugs, tumor cell resistance poses a major problem to efficacy of venetoclax. Primary resistance is present when tumor cells require anti-apoptotic BCL-2 proteins others than BCL-2 for survival. Naturally, only lymphocytes and melanocytes are dependent on BCL-2 expression, as shown in BCL-2 knockout mice. This might explain why venetoclax is most effective in mature lymphoma while most other tumors show primary resistance. Such primary resistance to venetoclax can also be caused by overexpression of pro-survival proteins other than BCL-2, like BCL-XL and/or MCL-1. As shown for CLL, these BCL-2 homologues can be induced by tumor microenvironment signals. Secondary resistance, in contrast, is acquired by tumor cells to escape previously effective BCL-2 inhibition. Several mechanisms such as BCL-2 mutations strongly lowering venetoclax affinity have been implicated in the development of secondary venetoclax resistance. Alternatively, BCL-XL and MCL-1 overexpression were noted in relapsed CLL patients who were previously treated with venetoclax. Therefore, development and administration of MCL-1/ BCL-XL inhibitors is much needed to overcome primary and secondary venetoclax resistances. Especially, MCL-1 inhibitors are highly awaited by oncologists since this protein plays an essential role in many tumor types (e.g. AML, multiple myeloma, non-small lung carcinoma).
MCL-1 was first identified during the differentiation of monocytes to macrophages in ML-1, a human myeloid leukemia cell line. Three isoforms of the gene have been reported; the most abundant anti-apoptotic MCL-1 long (MCL-1L) and two shorter pro-apoptotic isoforms (MCL-1 short, MCL-1 extra short). In addition, a truncated isoform was shown to localize at the mitochondrial matrix where it facilitates mitochondrial fusion and ATP synthesis. Genetic Mcl-1 deletion in mice revealed its essential role in many tissues, both during embryogenesis and in adult mice. Specifically, constitutive MCL-1 deficiency resulted in peri-implantation embryonic lethality, while targeted deletion in the fetal hematopoietic system resulted in loss of stem cells. When one Mcl-1 allele was deleted in adult mice, hematopoietic stem and progenitor cells (HSPCs) were depleted leading to the death of the animals within 2-3 weeks. For human HSPCs, only indirect evidence for the essential role of MCL-1 was given by the BH3 profiling method: Mitochondria isolated from human CD34+ cells were highly sensitive to NOXA BH3 peptides, which typically correlated with MCL-1 dependency.

Recently, a potent and specific MCL-1 inhibitor, S63845, was developed. It can efficiently kill a variety of tumor cell types such as multiple myeloma, lymphomas, leukemias and primary AML cells as well as to some extend solid cancers. Treatment of mice with S63845 resulted in only few side effects in vivo, which was rather unexpected considering the many roles of MCL-1 during development and for tissue homeostasis. Here, we extended these studies to human cells and focused on the hematopoietic system. Understanding hematotoxicities of novel anticancer drugs is crucial since suppression of hematopoiesis accounts for most treatment related morbidity and mortality. By using two different shRNA sequences and the MCL-1 inhibitor S63845, we consistently found that MCL-1 expression is essential for the survival of human stem and progenitor cells, especially during early stages of differentiation. In contrast, mature blood cells are less sensitive to MCL-1 inhibition. Of note, combined inhibition of MCL-1 and BCL-XL was synergistic and already low concentrations of both drugs resulted in profound stem and progenitor cell depletion.
Methods

Lentiviruses

pLeGO-hU6 lentiviral vector with huU6 promoter and GFP expression was used to generate shRNA expressing lentiviruses (Suppl. Table 1). CD34+ cells were transduced with the lentivirus (2x MOI 10, 24 hours each) and knockdown efficiencies were determined 24 hours later.

Isolation and culture of human CD34+ cells

Umbilical cord blood and bone marrow were obtained immediately after birth or from patients undergoing orthopedic surgery (age 44-90 years), respectively. Informed consent and approval from the ethics committee were given. CD34+ cells were isolated (MACS) from mononuclear cells (purity >90%). Cells were used either immediately or stored in liquid nitrogen (CS10 freezing medium, Sigma) for later use. Cells were cultured in serum free StemPro-34 medium supplemented with ES-FBS, penicillin/streptomycin (P/S; Invitrogen) SCF, FLT3L (each 200ng/ml), TPO (100ng/ml) and IL-3 (20ng/ml; Immunotools/Peprotech). Where indicated, the BH3-mimetics S63845 (SynMedChem), A-1155463 or ABT-199 (Sellekchem) were added.

Apoptosis assay

CD34+ cells were subjected to cytokine deprivation or treated with etoposide (VP16), tunicamycin, taxol, thapsigargin and Brefeldin A (BFA). After 0, 24 and 48 hours, cells were stained with AnnexinV (Biolegend) and 7-AAD (Sigma-Aldrich) to detect apoptosis. % specific apoptosis was calculated as: 100 x (% living cells under control condition - % living cells under treatment)/ % living cells under control condition. Control condition represented culture with ES-FBS, serum and cytokines.
Colony forming assays/ differentiating culture

Thousand CD34+ cells were seeded in MethoCult SF-H4436 medium. After 10-11 days, colony types (light microscopy) and total cell counts were determined. Percentages of HSPC, erythroid and myeloid cells were determined via flow cytometry (Suppl. Table 2).

Proliferating culture

CD34+ cells were cultured for 5-11 days in StemPro-34 medium supplemented with 10% ES-FBS, SCF, FLT3L, TPO and IL-3 (Immunotools/Peprotech). Medium was refreshed every three days. Cells were analyzed for GFP+ and immature populations (Suppl. Table 2).

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

RNA was isolated (Quick RNA Micro Prep kit Zymo Research) and reversely transcribed to cDNA (Quantitec-Reverse transcription kit, QIAgen). qRT-PCR was performed by using BIO-RAD (CFX96 Touch) RT-PCR detection system and SYBR Green master mix (Thermofisher). Expression of gene of interest was normalized to either 18S or 36B4.

Reverse transcriptase-Multiplex Ligation dependent Probe Amplification (RT-MLPA)

RNA samples from CD34+ cells cultured under different conditions were obtained by Fast Spin columns (Zymo Research). RT-MLPA was performed as per manufacturer’s instructions (MRC Holland, R011-C1). The resultant amplicons were separated by capillary electrophoresis (ABI-3130xl Genetic Analyzer). Analysis was conducted using Sequence Pilot (JSI Medical Systems). Sum of all peaks was taken as 100%, and single peaks were normalized accordingly.

Xenotransplantation

All experiments were performed after approval from local ethics committee and in compliance with the German law. Rag2−/−γc−/− mice were kept under specific pathogen-free conditions. Newborn mice were sub-lethally irradiated with 2.5Gy. After 6 hours, a progeny
of 1x10^5 transduced or untransduced human CD34+ cells were injected intrahepatically. Mice were sacrificed for analysis after 8 weeks.

**Flow Cytometry**

Single cell suspensions obtained from colony forming assays or hematopoietic organs from mice were surface stained with monoclonal antibodies: CD34 PE-Cy7(581), CD38 APC (HIT2), CD10 PE/APC (HI10a), CD45RA PerCP-Cy5.5 (HI100), CD90 APC-Cy7 (5E10), CD117 PE-Cy7 (104D2), CD71 APC (CY1G4), CD33 PE (WM53), CD14 APC (M5E2), CD115 BV421 (4D2-1E4), CD15 PeCy5 (W6D3), CD66b PerCP-Cy5.5 (G10F5), CD19 PE-Cy7 (HIB19), IgM APC-Cy7 (MHM-88), CD45 Biotin (HI30), CD45 PE-Cy7/V500 (30-F11) (Biolegend), CD235a BV421 (HIR2) (BD biosciences). Streptavidin PerCP-Cy5.5/V450 (Biolegend) was used as secondary antibodies. BD LSRFortessa and FlowJo were used for flow cytometry and analyses, respectively. The gating strategy was published earlier 31.

**Western Blot**

Purified proteins were size fractioned by 12% SDS-PAGE under reducing conditions and transferred onto PVDF membranes. Antibodies used: MCL-1 (D2W9E) rabbit mAb, BCL-XL (54H6), BCL-2 (D17C4), BFL1/A1 (D1A1C), α/β-tubulin or β-actin (13E5) (all rabbit, Cell signaling). A peroxidase-coupled goat anti-rabbit IgG secondary antibody was used (sc-2004, Santa Cruz).

**Statistics**

Statistical analyses were performed using the unpaired Mann-Whitney test in GraphPad Prism 7 software. P values less than 0.05 were considered statistically significant. Synergy of BCL-XL and MCL-1 inhibitors was calculated using the Bliss synergy score and the program SynergyFinder (https://synergyfinder.fimm.fi) 32.
Results:

**MCL-1 knockdown sensitizes human CD34\(^+\) cells selectively to ER stress**

Putative shRNA sequences specific for MCL-1 were tested in transfected HEK293T cells. For shRNA delivery into human CD34\(^+\) cells, a lentiviral system that allowed stable expression of the shRNA and GFP was used. Two different shRNA sequences, both binding to exon 3 of the human MCL-1 gene, were identified to reduce MCL-1 mRNA expression to 25-55\% in HEK293T and by 41-55\% in human cord blood-derived CD34\(^+\) HSPCs (Figure 1A). Knockdown of the Luciferase (Luci) gene was used as negative control. Efficient MCL-1 knockdown was confirmed on protein level in HEK293T and CD34\(^+\) cells and showed, at least in CD34\(^+\) cells, no relevant differences between the two shRNA sequences used (Figure 1B-C). Transduction efficiency was similar between the different viruses (Suppl. Figure 1B) but CD34\(^+\) cells transduced with shRNA specific for MCL-1 showed increased apoptosis rates 24 hours after transduction (Figure 1D). The surviving cells were cultured and treated for 24 and 48 hours with different cytotoxic drugs including the DNA damaging agent etoposide, the mitotic spindle inhibitor taxol and different compounds inducing ER stress (i.e. tunicamycin, thapsigargin and brefeldin A; Figure 1E-F). Interestingly, MCL-1 inhibition selectively increased sensitivity of CD34\(^+\) cells to ER stress (Figure 1E-F). While transduced GFP\(^+\) cells expressing MCL-1 shRNA were killed in a dose-dependent manner (Suppl. Figure 2A), GFP\(^+\) cells expressing Luci shRNA or non-transduced GFP\(^-\) cells did not undergo increased cell death upon ER stress (Suppl. Figure 2A-B). These findings indicate that MCL-1 inhibition increased cellular sensitivity in a stress-dependent and cell-intrinsic manner. Since knockdown of MCL-1 was not complete in CD34\(^+\) cells, we hypothesized that ER stress itself reduced MCL-1 levels, thereby leading to critical depletion of this protein once combined with the gene knockdown. Indeed, we found significant and dose-dependent downregulation of MCL-1 mRNA when CD34\(^+\) cells were treated with tunicamycin (Figure 1G). At the same time, tunicamycin lead to down-regulation of BCL-XL mRNA and upregulation of the BH3-only proteins PUMA and BMF (Suppl. Figure 2C). Upregulation of CHOP and PERK mRNA confirmed the presence of ER stress (Suppl. Figure 2D). In sum,
ER stress shifts the BCL-2 equilibrium towards apoptosis, which is initiated once levels of either MCL-1 (shown here) or BCL-XL (published earlier) \(^{31}\) are further reduced by RNA interference.

**Human HSPCs show impaired colony formation and differentiation upon MCL-1 knockdown**

To test the effect of MCL-1 knockdown on colony formation and differentiation of human CD34\(^+\) cells, we cultured 1000 transduced and sorted GFP\(^+\) cells for 11 days in MethoCult medium containing the cytokines SCF, IL-3, IL-6, EPO, G-CSF, GM-CSF, insulin and transferrin. The number of arising colonies were significantly lower when MCL-1 expression was inhibited (Figure 2A). All colony types were affected indicating that all multipotent and lineage-committed progenitor cell types were lost to a similar degree (Figure 2B). In addition, fewer cells could be harvested from plates (Figure 2C). Flow cytometry revealed that all cell types were reduced in number when MCL-1 was depleted (Suppl. Figure 3A). Since we noticed a relevant toxicity of the sorting procedure on lentivirally-transduced cells, we repeated the experiment using unsorted cells. In this approach, we could directly compare transduced GFP\(^+\) with untransduced GFP\(^-\) cells. Colony numbers and types were similar in all groups (Figure 2E-F) and also cell numbers were not consistently reduced when MCL-1 was downregulated (Figure 2G). However, while transduction rates were comparable (Suppl. Figure 3B), MCL-1 depleted GFP\(^+\) cells were selectively lost during the 11 days of MethoCult culture indicating their selective disadvantage (Figure 2H, Suppl. Figure 3B). Loss of MCL-1 affected all analyzed immature and mature cell types in a similar manner again, confirming that all progenitor cell types were dependent on MCL-1 expression (Figure 2H, Suppl. Figure 3C). To analyze whether MCL-1 depleted cells were lost immediately or progressively over time, we cultured them for only 5 days in MethoCult medium. At this early time point, only mild loss of GFP\(^+\) cells was observed independently of the lentivirus used (Figure 3A, left). This indicated that progenitor cells became more susceptible to MCL-1 inhibition once they progressed in their differentiation process. Accordingly, immature CD34\(^+\) cells and
specifically HSC and MPP were enriched in the first days of culture (Figure 3B, Suppl. Figure 3D-E). To inhibit differentiation but foster proliferation, CD34⁺ cells were cultured in the presence of the cytokines SCF (200 ng/ml), Flt3L (200ng/ml), TPO (100ng/ml) and IL-3 (20ng/ml). CD34 and GFP expression were measured after 5 and 11 days. Under this condition, %CD34⁺ cells remained high (Figure 3B, right) and GFP⁺ cells were not depleted in a relevant manner (Figure 3A, right). To exclude that expression of shRNA and, consecutively, MCL-1 knockdown were different in the two culture conditions, we measured \textit{MCL-1} mRNA after 5 days of culture. While we observed a stable MCL-1 knockdown by shRNA #3, the shRNA #4 showed less consistent results with reexpression of \textit{MCL-1} mRNA (Suppl. Figure 3F). However, no difference in knockdown efficiency was observed between the two culture conditions indicating that MCL-1 dependence of HSPCs indeed changed during proliferation and differentiation, respectively.

To understand why MCL-1 dependence was so different under the both culture conditions, we determined the composition of all BCL-2 proteins by RT-MLPA. As controls, we used freshly isolated CD34⁺ cells. Interestingly, both MCL-1 and BCL-XL were expressed at higher levels in cells stimulated to differentiate for 4 days (Figure 3C). Amongst the pro-apoptotic BCL-2 proteins, PUMA was highly upregulated under both culture conditions (i.e. differentiation and proliferation conditions) while BIM, BID and BAK1 were selectively upregulated under differentiation conditions (Figure 3D-E). Thus, it is possible that differentiation is associated with stronger pro-apoptotic signals that need to be counteracted by higher MCL-1 and BCL-XL levels. Based on its binding affinities, it is conceivable that MCL-1 expression is required to counteract BIM-mediated activation of BAK1.

**MCL-1 inhibition severely restricts HSPC engraftment in xenograft mice**

In order to determine the effects of MCL-1 inhibition on the engraftment potential of human CD34⁺ HSPCs, untransduced and transduced cells were intrahepatically transplanted into sublethally irradiated \textit{Rag2}⁻/⁻\textit{γc}⁻/⁻ mice. To reduce cell stress prior to transplantation, we waived the sorting procedure and transplanted GFP⁺ together with GFP⁻ cells. After 8 weeks,
xenograft mice were sacrificed and human engraftment was analyzed. Lentivirally transduced cells had a reduced potential to engraft but there were no differences between the viruses used (Figure 4A). As known from this model system, most cells differentiated into CD19+ B cells while fewer CD33+ myeloid cells and almost no CD3+ T cells arose (Figure 4B and data not shown). Cells expressing the control shRNA (Luci) engrafted and contributed to all lineages (Figure 4C-D). In contrast, cells expressing shRNA specific for MCL-1 did only show a very poor engraftment (Figure 4C). In line with the important role of MCL-1 for survival of immature progenitors with multipotent potential, all cell types found in the xenograft mice were equally affected (Figure 4D).

**MCL-1 inhibition limits survival of immature but not mature hematopoietic cells**

To determine the effects of MCL-1 inhibition on more mature hematological cell types, we used the specific MCL-1 inhibitor S63845. First, we treated freshly isolated immature CD34+ and mature CD34- cells with increasing doses of the inhibitor. While CD34+ cells were moderately sensitive when compared to cancer cell lines (e.g. IC50 in most multiple myeloma cell lines <0.1 µM) \(^2\)\(^8\), no apoptosis was induced after 24 and 48 hours in mature CD34- blood cells even when very high inhibitor doses were used (Figure 5A-B).

In a second approach, we let untreated CD34+ cells differentiate for 11 days in the MethoCult medium. Cells were then isolated and put into stem cell medium containing 10% FBS and cytokines (SCF, TPO, Flt3L, IL-3). Different concentrations of the MCL-1 inhibitor were added, and cell numbers were determined after 24 hours. Again, differentiated CD34- cells were much less sensitive than immature CD34+ cells (Figure 5C-D). As a consequence, only a mild and non-significant reduction in cell numbers was noted (Figure 5C) and both myeloid and erythroid cells were depleted only to a minor and non-significant degree (Figure 5D).

**Stem and progenitor cells from newborns and adults are equally sensitive to MCL-1 or BCL-XL inhibition**
Our experiments indicate a strong dependence of human HSPCs on MCL-1 expression, which is not unexpected considering the high relevance of MCL-1 for survival of murine HSPCs\(^{25, 26}\). However, other authors described an overall good tolerability of MCL-1 inhibitors in human HSPCs\(^{33-35}\). One reason for this discrepancy could be that we used cord blood derived CD34\(^+\) cells while bone marrow derived CD34\(^+\) cells of aged persons were used in other studies\(^33\). We therefore compared these two cell types with regards to protein levels of MCL-1 and other anti-apoptotic BCL-2 family members. Bone marrow CD34\(^+\) cells were obtained from patients with orthopedic problems (age range 44 to 90 years). While MCL-1 and BCL-XL levels were identical in both cell types and A1 was not expressed, BCL-2 levels were higher in adult than newborn HSPCs (Figure 6A).

Next, we performed comparative functional studies using the MCL-1 inhibitor S63845, the BCL-XL inhibitor A-1155463 and the BCL-2 inhibitor ABT-199. By treating bone marrow immature CD34\(^+\) and differentiated CD34\(^+\) cells with the MCL-1 inhibitor for 24 and 48 hours, we obtained similar results as with cord blood cells (compare Figure 6B with 5A/B). Chemical inhibition of MCL-1 also confirmed our RNAi experiments: when we added the inhibitor S63845 to cord blood CD34\(^+\) cells cultured in MethoCult medium, colony formation was impeded in a dose dependent manner (compare Figure 6C with Figure 2). Immature cell types including hematopoietic stem cells, multipotent progenitors and mixed lymphoid progenitors were significantly reduced in numbers (Figure 6C, right panel). Similarly, all emerging erythroid and myeloid cells (Figure 6C, right panel) were depleted in a dose dependent manner. Importantly, there was no difference in MCL-1 inhibitor sensitivity in CD34\(^+\) cells derived from cord blood (Figure 6C) or bone marrow (Figure 6D).

We have shown earlier that also BCL-XL is important to keep human cord blood CD34\(^+\) cells alive\(^31\), a finding that was unexpected considering its dispensable role for mouse HSPCs\(^{36-38}\). We now extended our studies to bone marrow derived cells and showed that CD34\(^+\) cells were more sensitive to the BCL-XL inhibitor A-1155463 than CD34\(^-\) cells (Figure 7A). We compared colony forming potential of cord blood and bone marrow derived CD34\(^+\) cells and observed no difference between the two cell types: BCL-XL inhibition resulted in significant
reduction of colony (Figure 7B) and cell numbers (Figure 7C), independently of the source of the human HSPCs. Notably, effects on colony formation were less pronounced than those caused by MCL-1 inhibition. As published earlier, immature CD34+ (Figure 7D) as well as mature erythroid cells (Figure 7E) were more severely affected than myeloid cells (Figure 7F).

Finally, the BCL-2 inhibitor ABT-199 did not negatively affect survival and colony formation of cord blood or bone marrow derived CD34+ cells, even when used in the high concentration of 1µM ABT-199 (Suppl. Figure 4). This is consistent with the relatively mild myelosuppressive effects of venetoclax observed in clinical trials\(^{39}\).

**Synthetic lethality of MCL-1 and BCL-XL inhibitors in human hematopoietic stem and progenitor cells**

We noted a striking functional homology of MCL-1 and BCL-XL for survival of human HSPCs and concluded that combined inhibition of both anti-apoptotic proteins could result in complete depletion of colony-forming stem and progenitor cells. To test this, we treated cord blood-derived CD34+ cells with increasing doses of the MCL-1 inhibitor S63845, together with increasing doses of the BCL-XL inhibitor A-1155463. Apoptosis induction was determined 24 hours later (Figure 8A). Using the SynergyFinder (https://synergyfinder.fimm.fi) a dose response matrix was calculated (Figure 8B). The resulting Bliss score of 21.26 indicated strong synergy between both inhibitors. Synthetic lethality was confirmed in colony forming assays, both with cord blood and bone marrow derived CD34+ cells. Already at concentrations of 0.1 µM each, the drug combination resulted in a substantial loss of colony forming cells (Figure 8C-D, in comparison with Figure 6B-C and Figure 7).

To determine the number of immature cells with self-renewal potential that survived BCL-XL and/or MCL-1 inhibition, we used 10,000 cells isolated from primary colonies for serial colony forming assays. Interestingly, only BCL-XL inhibition in the first plating resulted in depletion of progenitor cells able to form colonies in the second plating. However, there was a synergistic effect when this was combined with MCL-1 inhibition (Suppl. Figure 5).
Discussion:
Because of the narrow spectrum of cancer entities susceptible to venetoclax, specific MCL-1 and BCL-XL inhibitors are eagerly awaited by oncologists. Observations made in genetically modified mice, however, indicate that inhibition of MCL-1 or BCL-XL could have more severe side effects than BCL-2 inhibition. Mice deficient for either MCL-1 or BCL-XL have severe developmental phenotypes while BCL-2 deficient mice lack lymphocytes and melanocytes but are normal otherwise.\(^{10,40,41}\) Hematopoietic toxicity of anticancer drugs is responsible for most therapy-related morbidity and mortality and a common reason for treatment delays or dose reduction. We, therefore, consider it important to generate preclinical data to evaluate the hematotoxicity profile of such novel drugs. Recently, we described the detrimental effects of BCL-XL inhibition on human HSPCs and erythroid progenitors.\(^{31}\)

Here, we dissected the effects of MCL-1 inhibition on the different immature and mature hematological cell types. By using an RNAi approach and the specific small molecule inhibitor S63845, we consistently found that MCL-1 expression is crucial for multipotent stem and progenitor cells, as well as for myeloid progenitors, while erythroid progenitors are less susceptible to MCL-1 inhibition. During later stages of blood cell differentiation, MCL-1 becomes dispensable for cell survival. Interestingly, we noted reexpression of \textit{MCL-1} mRNA after some days of culture, when shRNA #4 was used, while the shRNA #3 resulted in a stable knockdown. Nevertheless, the resulting phenotype was strikingly similar indicating that the loss of stem and multipotent progenitors occurs early after MCL-1 depletion and cannot be compensated by later MCL-1 reexpression.

Looking more closely at the stem and progenitor cell compartment, we noted that cells that specifically enter the differentiation process are highly dependent on MCL-1 expression, while proliferating CD34\(^+\) cells remain fairly resistant. What is the reason for this difference? It is possible that the differentiation process is associated with increased stress levels reflected by accumulation of activated BH3-only proteins. Alternatively, it is possible that the cytokines TPO, FLT3L, SCF and IL3, which induce cell proliferation and are used for the CD34\(^+\) cell culture, do not only induce proliferation but confer CD34\(^+\) cells also with survival
signals thereby rendering them independent of MCL-1 expression. Indeed, we have shown earlier that these cytokines induce BCL-XL mRNA upregulation and at the same time repress expression of the pro-apoptotic BCL-2 proteins BIM and BMF. Also in this study, BIM mRNA levels were lower and BCL-XL mRNA levels higher when cells were cultured in the presence of TPO, FLT3L, SCF and IL3. It was recently shown by Delbridge et al that MCL-1 expression in murine HSPCs is critically required to counteract PUMA-induced apoptosis. While mice lacking only one Mcl-1 allele in the hematopoietic system rapidly succumbed to bone marrow failure, additional deletion of both Puma alleles rescued all animals. However, our in vitro studies showed strong upregulation of PUMA mRNA in human CD34+ cells irrespective of the culture conditions and without being reflected by their MCL-1 addiction. This indicates that although there is a conserved role of MCL-1 for survival of murine and human HSPCs, its function in human cells might not be restricted to inhibition of PUMA.

We wondered whether also the most immature stem cells, those able to self-renew, depend on MCL-1 expression. While it is one limitation of in vitro model systems that dormant stem cells cannot be analyzed reliably, we could show by serial colony forming assays that cells able to self-renew were dependent rather on BCL-XL than on MCL-1 expression. This is in contrast to findings published by Campbell et al who attributed the loss of immature stem and progenitor cells upon MCL-1 inhibition to their reduced propensity to self-renew.

While human cord blood-derived HSPCs were severely affected by MCL-1 inhibition in our hands, other authors claimed good tolerability of S63845 in non-malignant hematopoietic cells. We hypothesized that this discrepancy was caused by cell-intrinsic differences between cord blood HSPCs used in our study and bone marrow HSPCs derived from aged persons used in other studies. We therefore compared CD34+ cells isolated from cord blood and bone marrow with regards to protein expression of anti-apoptotic BCL-2 proteins and their susceptibility towards different BH3-mimetics. Adult HSPCs had higher levels of BCL-2. Nevertheless, BCL-2 inhibition had no negative effects on colony forming potential of aged HSPCs. MCL-1 and BCL-XL levels were similar between the two types of HSPCs while
BFL1/A1 was not expressed. Importantly, inhibition of either MCL-1 or BCL-XL significantly impeded colony formation of both neonatal and adult HSPCs and no cell type-specific difference could be noted.

What do our results implicate? First, the resistance of mature blood cells to S63845 suggests that immediate hematological side effects might be mild in patients treated with MCL-1 inhibitors. The depletion of immature progenitor cells, however, can be associated with a relevant risk of severe cytopenias, although they might not occur immediately. To avoid excessive or even permanent bone marrow damage, repeated bone marrow analyses might be useful to detect hypocellularity as early as possible. Second, MCL-1 and BCL-XL inhibitors have synergistic rather than additive effects on human CD34+ HSPCs. Synthetic lethality of two BH3-mimetics was shown for multiple tumors: The combination of BCL-2 and MCL-1 inhibitors showed synergistic effects in a vast variety of malignancies, amongst them mantle cell lymphoma, T-cell prolymphocytic leukemia, multiple myeloma, high risk B-ALL, AML and melanoma. BCL-XL and MCL-1 inhibitors were successfully combined in multiple myeloma, melanoma, prostate cancer and multiple pediatric tumors. These observations make the combination of different BH3-mimetics very attractive. Yet, our results strongly point towards synthetic lethality also in healthy tissues. Specifically, combined BCL-XL and MCL-1 inhibition might be detrimental for the healthy hematopoietic tissue. This fact should be kept in mind when new clinical trials are designed.

Most data available so far, including our own, were either performed in vitro or in artificial mouse models. Clinical data gathered from already initiated phase I trials (e.g. NCT03218683, NCT02675452, NCT03465540, NCT02979366) will provide better insight both into the anticancer efficacy of MCL-1 inhibitors and their frequent side effects. Importantly, some trials using small molecule MCL-1 inhibitors were placed on hold by the FDA in September 2019 because of cardiac toxicity. No data on hematological toxicities are published yet. Based on the very promising preclinical data, one could speculate that the overall benefit-to-risk profile of MCL-1 inhibitors will be favorable, especially for
tumors otherwise refractory to chemotherapy. In case of severe irreversible hematopoietic damage created by MCL-1 inhibitors, they still could be used within high-dose chemotherapy regimens given prior to autologous or allogeneic hematopoietic stem cell transplantations.

References

Figure legends:

Figure 1: MCL-1 inhibition selectively sensitizes human CD34+ cells to ER-stress

(A) HEK293T cells were transfected with plasmids expressing shRNA specific for Lucifierase (shLuci) or human MCL-1 (shM#3 or shM#4). MCL-1 mRNA expression was determined in sorted GFP+ cells and normalized to 36B4 reference gene. Bars represent mean ±SEM; n=5 from 5 independent experiments. Human cord blood-derived CD34+ cells were transduced with the corresponding lentiviruses. GFP+ cells were sorted 24 hours after transduction, and...
knockdown efficiency of MCL-1 was determined by qRT-PCR. mRNA expression was normalized to 18S. Bars represent mean ±SEM; n=2-4 from 4 independent experiments. Mann–Whitney test was performed (*p<0.05). (B-C) MCL-1 protein levels were determined in HEK293T (B) and CD34+ (C) GFP+ cells. (D) Apoptosis measurement performed in CD34+ cells 24 hours after lentiviral transduction revealed that 14-19% of cells undergo apoptosis early after MCL-1 depletion. Bars represent mean ±SEM; n=4 from 4 independent experiments. (E-F) Transduced CD34+ cells (transduction efficiency 45-65%) were either cultured under optimal conditions (cytokines and 10% serum) or under conditions of stress; in the presence of serum but deprived of cytokines, etoposide (0.5 µg/ml), taxol (0.125 µg/ml), tunicamycin (0.5 (l) and 1 µg/ml (ll)), thapsigargin (3 μM) or brefeldin A (BFA; 0.5 µg/ml). Apoptosis in GFP+ cells was determined by flow cytometry using Annexin V and 7-AAD staining 24 hours (E) and 48 hours (F) later. Bars represent mean ± SEM; n=3-8 from 8 independent experiments. Mann–Whitney test was performed; *p<0.05, **p<0.01, ***p<0.001. (G) RNA was isolated from CD34+ cells treated with increasing concentrations of tunicamycin and used for qRT-PCR. MCL-1 mRNA expression was normalized to 18S. Bars represent mean ± SEM; n=4 from 4 independent experiments. Mann–Whitney test was performed; p*<0.05

Figure 2: MCL-1 is essential for all hematopoietic progenitor cells

(A-C) Lentivirally transduced human CD34+ cells were sorted for GFP-expression. GFP+CD34+ cells were seeded in MethoCult medium (1000 cells each). (D-G) Alternatively, unsorted cells were plated. (A, D) After 11 days of culture, colonies were counted by light microscopy. (B, E) Based on morphological findings, the following colony types were identified by light microscopy: GEMM: granulocytic-erythroid-megakaryocytic-monocytic, GM: granulocytic–monocytic, G: granulocytic, E: erythroid, M: monocytic. (C, F) Cells were dissolved from the semisolid medium and counted by hemocytometer. (G) The different hematopoietic cell types were determined by flow cytometry. %GFP+ cells are shown within each of the following cell populations: HSC; hematopoietic stem cells (CD34+CD38-CD45RA-
CD90+), MPP: multipotent progenitors (CD34+CD38−CD45RA−CD90+), GM: granulocytic–monocytic progenitors (CD34+CD33+CD115+), CFU-G: colony forming unit-granulocytes (CD34−CD33−CD15+CD115+), M: monocytes (CD34−CD33−CD14+CD115+), immE: immature erythrocytes (CD71hiCD235a−), matE: mature erythrocytes (CD71+CD235a+). Bars represent mean ± SEM, n=6 (A-C) from 6 independent experiments and n=4 (D-G) from 4 independent experiments. Mann–Whitney test was performed; *p<0.05, **p<0.01

**Figure 3: MCL-1 expression is more important for differentiating than for proliferating CD34+ cells**

(A) Sorted CD34+GFP+ cells were either subjected to differentiating or proliferating culture conditions. To induce differentiation, cells were cultured in semisolid MethoCult plates for 5 days (3000 cells seeded per plate) or 11 days (1000 cells seeded per plate). To foster proliferation, cells were cultured in stem cell medium containing 10% serum and SCF, FLT3L (200 ng/ml each), TPO (100 ng/ml) and IL-3 (20 ng/ml). After 5 and 10 days of culture, %GFP+ cells were determined by flow cytometry. (B) The fraction of CD34+ cells was determined within GFP+ cells at each time point. (C-E) Untransduced CD34+ cells were subjected to the two different culture conditions and harvested at the indicated time points. mRNA was used for RT-MLPA designed to determine levels of apoptosis genes. Anti-apoptotic BCL-2 proteins (C), BH3-only proteins (D) and pro-apoptotic effector proteins (E) are shown. Freshly isolated CD34+ cells were used as controls. Bars represent mean ± SEM from n=4 from 4 independent experiments. Mann–Whitney test was performed; *p<0.05, **p<0.01.

**Figure 4: Human CD34+ cells lacking MCL-1 show poor engraftment in xenograft mice**

(A-D) Lentivirally transduced or untransduced human HSPC were transplanted intrahepatically into newborn Rag2−/−γc−/− mice after sub-lethal irradiation. Mice were sacrificed 8 weeks after transplantation and bone marrow (BM) and spleen populations were analyzed. By using antibodies specific for human or murine CD45, % human engraftment
was determined (A). The various human hematopoietic populations were determined within the huCD45$^+$ cells using flow cytometry (B). GFP expression was determined in huCD45$^+$ cells (C) and in each subpopulations (D). Bars represent mean ± SEM, n = 9-13 from 8 independent experiments. Mann–Whitney test was performed; *$p<0.05$, **$p<0.01$.

**Figure 5: Survival of mature hematopoietic cells is independent of MCL-1**

(A-B) Freshly isolated cord blood was subjected to density gradient centrifugation and mononuclear cells were divided into CD34$^+$ and CD34$^-$ cells using MACS technology. Both cell fractions were treated with the indicated concentrations of the MCL-1 inhibitor S63845. After 24 (A) and 48 (B) hours, %living cells were determined by flow cytometry using Annexin V/7-AAD. Bars represent mean ± SEM; n=3-6 from 6 independent experiments. (C-D) CD34$^+$ cells were differentiated in MethoCult culture. After 11 days, differentiated cells were isolated and treated with S63845 for 24 hours. Total cell numbers (C) were determined and erythroid and myeloid cell populations (D) were analyzed by flow cytometry (n=5 from 5 indep. experiments). Bars represent mean ± SEM. Mann–Whitney test was performed; *$p<0.05$, **$p<0.01$ ***$p<0.001$

**Figure 6: MCL-1 is essential for survival of both cord blood- and bone marrow-derived human CD34$^+$ cells**

(A) Protein levels of the anti-apoptotic BCL-2 family members MCL-1, BCL-XL, BCL-2 and BFL1/A1 were determined in CD34$^+$ cells isolated from both cord blood and bone marrow. β-actin served as a loading control. (B) Freshly isolated bone marrow was subjected to density gradient centrifugation and mononuclear cells were divided into CD34$^+$ and CD34$^-$ cells using MACS technology. Both cell fractions were treated with the indicated concentrations of the MCL-1 inhibitor S63845. After 24 (upper panel) and 48 (lower panel) hours, %living cells were determined by flow cytometry using Annexin V/7-AAD. Bars represent mean ± SEM; n=6-7 from 7 independent experiments. (C-D) Human CD34$^+$ cells isolated from either cord blood (C) or bone marrow (D) were differentiated in MethoCult medium containing 0.1 or 1μM of
S63845. As controls, untreated and DMSO-treated cells were used (n=7 from 7 independent experiments). After 11 days, total colony numbers (left) and total cell numbers (middle) were determined using light microscopy and hemocytometry, respectively. Different immature and differentiated cell types were determined by flow cytometry, and their absolute cell numbers were calculated (right). The following cell types were determined; HSC: hematopoietic stem cells (CD34+CD38-CD45RA-CD90+), MPP: multipotent progenitors (CD34+38-CD45RA/+10+), MLP: mixed lymphoid progenitors (CD34+CD38-CD45RA+CD10+), GM: granulocytic-monocytic progenitors (CD34+CD33+CD10+), M: monocytes (CD34-CD33+CD14+CD115+), immE: immature erythrocytes (CD71+CD235a-), matE: mature erythrocytes (CD71+CD235a+). Bars represent mean ± SEM. Mann-Whitney test was performed; *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001.

**Figure 7: BCL-XL inhibition impedes colony formation and survival of erythroid cells**

(A) Freshly isolated bone marrow was subjected to density gradient centrifugation and mononuclear cells were divided into CD34+ and CD34- cells using MACS technology. Both cell fractions were treated with the indicated concentrations of the BCL-XL inhibitor A-1155463. After 24 hours, %living cells were determined by flow cytometry using Annexin V/7-AAD. Bars represent mean ± SEM; n=3-4 from 4 independent experiments. (B-F) Human CD34+, either derived from cord blood or bone marrow, were differentiated in MethoCult culture containing 0.5 or 1.5µM of A-1155463. As controls, untreated and DMSO-treated cells were used (n=6-7 from 7 independent experiments). After 11 days, total colony numbers (B) and total cell numbers (C) were determined using light microscopy and hemocytometry, respectively. Different cell types were determined by flow cytometry, and their absolute cell numbers were calculated (D-F). The following cell types were determined; immature CD34+ cells, monocytes (CD34+CD33+CD14+CD115+), BCL-XL inhibition impedes colony formation and survival of erythroid cells
Figure 8: Synergistic action of MCL-1 and BCL-XL inhibitors on human hematopoietic stem and progenitor cells.

(A-B) Cord blood CD34+ cells were treated with increasing doses of the inhibitors S63845 and A-1155463 to determine synergism between the drugs. (A) Apoptosis was measured 24h after treatment using AnnexinV/7AAD. % specific apoptosis was calculated. (B) Dose response matrix was determined using the web application SynergyFinder. (n=4 from 4 independent experiments). (C-D) Human CD34+, either cord blood- or bone marrow-derived, were differentiated in MethoCult culture (1000 cells seeded per plate) in the presence of a combination of the MCL-1 inhibitor S63845 and the BCL-XL inhibitor A-1155463 (0.1µM or 1µM each). After 10 days, total colony numbers (C) and total cell numbers (D) were determined by light microscopy and hemocytometry, respectively. Bars represent mean ± SEM from n=6-7 from 6 independent experiments. Mann–Whitney test was performed. *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001
Suppl. Figure 1:

(A) BH3-mimetics (red) inhibit anti-apoptotic BCL-2 proteins (black, rectangular) with specific binding activities, thereby acting like BH3-only proteins (white). As a consequence, BAX and BAK are activated and mitochondrial outer membrane permeabilization (MOMP) is initiated.

(B) Human cord blood-derived CD34+ cells were transduced with the according lentiviruses. Transduction efficiency was measured by GFP expression 24h after the end of viral transduction via flow cytometry. Bars represent mean ±SEM; n=31 from 31 independent experiments.
Suppl. Figure 2:
(A) Transduced CD34+ cells were treated with increasing doses of the ER-stress inducer tunicamycin ranging between 0.5 and 3 µg/ml. 24 hours later, apoptosis and GFP expression were detected by flow cytometry. Specific apoptosis of the GFP+ cells was determined. Bars represent mean ± SEM (n=2)
(B) Transduced CD34+ cells were either cultured under optimal conditions (cytokines and 10% serum) or under conditions of stress; in the presence of serum but deprived of cytokines, etoposide (0.5 µg/ml), taxol (0.125 µg/ml), tunicamycin (0.5 (I) and 1 µg/ml (II)), thapsigargin (3 µM) or brefeldin A (BFA; 0.5 µg/ml). Apoptosis in GFP- (untransduced) cells was determined by flow cytometry using Annexin V and 7-AAD staining 24 hours later. Bars represent mean ± SEM; n=3-8 from 8 independent experiments.
(C) CD34+ cells were subjected to 1 µM tunicamycin and harvested after 12 hours. mRNA was used for RT-MLPA designed to determine levels of apoptosis genes. Anti-apoptotic BCL-2 proteins (first panel), BH3-only proteins (second panel) and pro-apoptotic effector proteins (third panel) are shown. Untreated CD34+ cells were used as controls. Bars represent mean ± SEM from n=3-4 from 4 independent experiments.
(D) CD34+ cells were subjected to 1 µM tunicamycin and harvested after 12 hours. mRNA was used for qRT-PCR of ER-stress related genes. CHOP and PERK mRNA expression was normalized to 18S. Bars represent mean ± SEM; n=4 from 4 independent experiments.
Suppl. Figure 3:

(A) Lentivirally transduced human CD34+ cells were sorted for GFP expression and GFP+CD34+ cells were seeded in MethoCult medium (1000 cells each).

(B–C) Alternatively, unsorted cells were plated. Different immature cell types were determined by flow cytometry, and their absolute cell numbers were calculated. Bars represent mean ± SEM, n=6 (A) from 6 independent experiments and n=4 (B–C) from 4 independent experiments. Mann–Whitney test was performed; *p<0.05. The following cell types were determined; HSC: hematopoietic stem cells (CD34+CD38-CD45RA-CD90+), MPP: multipotent progenitors (CD34+38-CD45RA-CD90-), GM: granulocytic–monocytic progenitors (CD34+CD33+CD115+), CFU-G: colony forming unit-granulocytes (CD34-CD33+CD15+CD115), M: monocytes (CD34-CD33+CD14+CD115-), immE: immature erythrocytes (CD71hiCD235a-), matE: mature erythrocytes (CD71+CD235a+)

(D–F) Lentivirally transduced human CD34+ cells were either subjected to differentiating or proliferating culture conditions. To induce differentiation, cells were cultured in semisolid MethoCult plates for 5 days (10.000 cells seeded per plate). To foster proliferation, cells were cultured in stem cell medium containing 10% serum and SCF, FLT3L (200 ng/ml each), TPO (100 ng/ml) and IL-3 (20 ng/ml). After 5 and 10 days, percentages of HSC (D) and MPP (E) were determined by flow cytometry. After 5 days, knockdown efficiency of MCL-1 was determined in sorted GFP+ cells by qRT-PCR. mRNA expression was normalized to 18S. (F) Bars represent mean ±SEM; n=4 from 4 independent experiments. Mann–Whitney test was performed. *p<0.05
Suppl. Figure 4:

(A) Freshly isolated bone marrow was subjected to density gradient centrifugation and mononuclear cells were divided into CD34+ and CD34- cells using MACS technology. Both cell fractions were treated with the indicated concentrations of the BCL-2 inhibitor ABT-199. After 24 hours, %living cells were determined by flow cytometry using Annexin V/7-AAD. Bars represent mean ± SEM; n=3-4 from 4 independent experiments.

(B-F) Human bone marrow derived CD34+ cells were differentiated in MethoCult culture containing 1µM of ABT-199. As controls, untreated and DMSO-treated cells were used (n=3 from 3 independent experiments). After 11 days, total colony numbers (B) and total cell numbers (C) were determined using light microscopy and hemocytometry, respectively. Different cell types were determined by flow cytometry, and their absolute cell numbers were calculated (D-F). The following cell types were determined; immature CD34+ cells, monocytes (CD34-CD33+CD14+CD115-) and mature erythrocytes (CD71+CD235a+).
Suppl. Figure 5:
Human CD34+ were differentiated in MethoCult culture (1000 cells seeded per plate) in the presence of the MCL-1 inhibitor S63845 (0.1µM or 1µM), the BCL-XL inhibitor A-1155463 (0.5µM or 1.5µM) or a combination of both inhibitors (0.1µM or 1µM each). After 10 days, cells were isolated from the MethoCult medium and washed. 10,000 cells were replated into fresh MethoCult medium. No inhibitors were added to this culture. After a 10 days culture, colony numbers were determined by light microscopy. Bars represent mean ± SEM, n =5 from 5 independent experiments. Mann–Whitney test was performed. *p<0.05
### Supplementary Table 1: Oligonucleotides and Primers

<table>
<thead>
<tr>
<th>Oligonucleotides (Eurofins/Apara)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Luci shRNA</strong> Top:</td>
</tr>
<tr>
<td><strong>MCL-1#3 shRNA</strong> Top:</td>
</tr>
<tr>
<td><strong>MCL-1#4 shRNA</strong> Top:</td>
</tr>
<tr>
<td><strong>qRT-PCR Human Primers (Eurofins/Apara/biomers)</strong></td>
</tr>
<tr>
<td><strong>18S</strong> Forward:</td>
</tr>
<tr>
<td>Reverse:</td>
</tr>
<tr>
<td><strong>36B4</strong> Forward:</td>
</tr>
<tr>
<td>Reverse:</td>
</tr>
<tr>
<td><strong>MCL-1</strong> Forward:</td>
</tr>
<tr>
<td>Reverse:</td>
</tr>
<tr>
<td><strong>PERK</strong> Forward:</td>
</tr>
<tr>
<td>Reverse:</td>
</tr>
<tr>
<td><strong>CHOP</strong> Forward:</td>
</tr>
<tr>
<td>Reverse:</td>
</tr>
<tr>
<td><strong>Sequencing Primers (Eurofins)</strong></td>
</tr>
<tr>
<td><strong>pLeGOhU6</strong> Reverse:</td>
</tr>
</tbody>
</table>
## Supplementary Table 2: Hematopoietic population definitions

<table>
<thead>
<tr>
<th>Population</th>
<th>Abbreviation</th>
<th>Characterization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematopoietic Stem Cells</td>
<td>HSC</td>
<td>CD34⁺ CD38⁻ CD45RA⁻ CD90⁺</td>
</tr>
<tr>
<td>Mixed Lymphoid Progenitor</td>
<td>MLP</td>
<td>CD34⁺ CD38⁻ CD45RA⁺ CD10⁺</td>
</tr>
<tr>
<td>Multipotent Progenitors</td>
<td>MPP</td>
<td>CD34⁺ CD38⁻ CD45RA⁻ CD90⁻</td>
</tr>
<tr>
<td>Colony Forming Unit Granulocytes</td>
<td>CFU-G</td>
<td>CD34⁻ CD33⁺ CD15⁺ CD115⁻</td>
</tr>
<tr>
<td>Granulocytic Monocytic precursors</td>
<td>GM</td>
<td>CD34⁺ CD33⁺ CD115⁺</td>
</tr>
<tr>
<td>Monocytes/Macrophage precursors</td>
<td>M</td>
<td>CD34⁻ CD33⁺ CD14⁺ CD115⁻</td>
</tr>
<tr>
<td>Immature erythroid cells</td>
<td>-</td>
<td>CD71^{high} CD235a⁻</td>
</tr>
<tr>
<td>Mature erythroid cells</td>
<td>-</td>
<td>CD71⁺ CD235a⁺</td>
</tr>
</tbody>
</table>